NEJM· @NEJM · X·· 24 天前精选AI 评分78
AI 导读
ESMO26公布的3期VOLGA试验结果显示,肌层浸润性膀胱癌患者接受围手术期度伐利尤单抗联合新辅助恩诺单抗维多汀(enfortumab vedotin)治疗,24个月无事件生存率为63.5%,单纯手术组为45.1%。完整3期结果已发布。
推荐理由
VOLGA 3期数据显示围手术期联合方案将24个月无事件生存率从45.1%提升至63.5%,可供比较肌层浸润性膀胱癌围手术期治疗选择。
正文
Presented at #ESMO26:
In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: https://nej.md/4z7dQFm
@myESMO
来源:NEJM · x.com